Radio

A multi-stage randomised trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.

RadIO logo

Study Overview and Summary

Chief Investigator: Professor Nicholas James
Sponsor: University of Birmingham
Funders: NIHR Health Technology Assessment (HTA)
Disease Site: Bladder Cancer
Study Type:

Randomised Phase II/III Clinical Study of a Non-Investigational Medicinal Product

Status:  
UKCRN Study ID: (if applicable)  N/A
ISRCTN Referance Number:  
Open to new sites? Yes
Recruitment start date:  
Anticipated Recruitment end date  
CRCTU Study Management Team: Late Phase Trial Management Team A
Study E-mail Address: Radio@trials.bham.ac.uk

Study Summary

Clinical study protocols are complex technical documents which should only be used for the treatment of subjects taking part in the study. Patients who are interested in taking part in the study are advised to talk to their health care professional or refer to the CancerHelp website, see link below.

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference. 

  •  View Study Protocol [.pdf]
  •  View Patient Information Sheet (PIS) [.pdf]

    For information about how we process your personal data, please view the Unit’s privacy notice.

More information